Repository logo
 
Publication

I-Move towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in europe, 2008-9

2009-11Journal article Open access
Simple item page
dc.contributor.authorKissling, E.
dc.contributor.authorValenciano, M.
dc.contributor.authorFalcao, J.
dc.contributor.authorLarrauri, A.
dc.contributor.authorWidgren, K.
dc.contributor.authorPitigoi, D.
dc.contributor.authorOroszi, B.
dc.contributor.authorNunes, Baltazar
dc.contributor.authorSavulescu, C.
dc.contributor.authorMazick, A.
dc.contributor.authorLupulescu, E.
dc.contributor.authorCiancio, B.
dc.contributor.authorMoren, A.
dc.date.accessioned2012-02-28T15:52:29Z
dc.date.available2012-02-28T15:52:29Z
dc.date.issued2009-11
dc.description.abstractWithin I-MOVE (European programme to monitor seasonal and pandemic influenza vaccine effectiveness (IVE)) five countries conducted IVE pilot case-control studies in 2008-9. One hundred and sixty sentinel general practitioners (GP) swabbed all elderly consulting for influenza-like illness (ILI). Influenza confirmed cases were compared to influenza negative controls. We conducted a pooled analysis to obtain a summary IVE in the age group of >or=65 years. We measured IVE in each study and assessed heterogeneity between studies qualitatively and using the I2 index. We used a one-stage pooled model with study as a fixed effect. We adjusted estimates for age-group, sex, chronic diseases, smoking, functional status, previous influenza vaccinations and previous hospitalisations. The pooled analysis included 138 cases and 189 test-negative controls. There was no statistical heterogeneity (I2=0) between studies but ILI case definition, previous hospitalisations and functional status were slightly different. The adjusted IVE was 59.1% (95% CI: 15.3-80.3%). IVE was 65.4% (95% CI: 15.6-85.8%) in the 65-74, 59.6% (95% CI: -72.6 -90.6%) in the age group of >or=75 and 56.4% (95% CI: -0.2-81.3%) for A(H3). Pooled analysis is feasible among European studies. The variables definitions need further standardisation. Larger sample sizes are needed to achieve greater precision for subgroup analysis. For 2009-10, I-MOVE will extend the study to obtain early IVE estimates in groups targeted for pandemic H1N1 influenza vaccination.por
dc.description.sponsorshipEuropean Centre for Disease Prevention and Control (ECDC)por
dc.identifier.citationEuro Surveill. 2009 Nov 5;14(44). pii: 19388por
dc.identifier.issn1560-7917
dc.identifier.urihttp://hdl.handle.net/10400.18/700
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherEuropean Centre for Disease Prevention and Controlpor
dc.relationI-MOVE (influenza: monitoring vaccine effectiveness in Europe)por
dc.relation.publisherversionhttp://www.eurosurveillance.org/viewarticle.aspx?articleid=19388por
dc.subjectEstados de Saúde e de Doençapor
dc.subjectEpidemiologiapor
dc.subjectInfluenzapor
dc.subjectSeasonal Vaccinepor
dc.subjectPandemic Influenza Vaccinepor
dc.subjectEffectivenesspor
dc.titleI-Move towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in europe, 2008-9por
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage8por
oaire.citation.startPage1por
oaire.citation.titleEurosurveillancepor
rcaap.rightsopenAccesspor
rcaap.typearticlepor

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
“I-MOVE” towards monitoring seasonal and pandemic influenza vaccine effectiveness.pdf
Size:
310.21 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DEP - Artigos em revistas internacionais